In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing

Starting soon

Conditions studied: Carcinoma, Non-Small-Cell Lung, EGFR Gene Mutation

In brief

The PRECISE-EGFR study is a prospective, observational project designed to generate patient-derived in vitro models (cell cultures and organoids) from individuals with non-small cell lung cancer (NSCLC) carrying EGFR mutations. These models will be used to evaluate sensitivity to different anti-EGFR therapies and explore mechanisms of drug resistance. Using residual biological samples collected during routine clinical practice, the study will not interfere with patient care. Researchers will also compare the molecular characteristics of the models with the original tumors to ensure reliability. The overall aim is to improve precision oncology approaches, identifying the most effective treatments for specific EGFR mutation subtypes while minimizing toxicity and resistance.

Key facts

Study ID

NCT07697716

Run by

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

People needed

30

Starts

2026-09-01

Expected to finish

2029-12-31

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Diagnosis of non-small cell lung cancer (NSCLC), regardless of the line of treatment.
• Documented presence of an EGFR mutation.
• Availability of residual biological material obtained from diagnostic or therapeutic procedures performed as part of routine clinical practice.
• Signed written informed consent for study participation.

You may not qualify if…

• Patients who have not provided written informed consent will be excluded from the study.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.